胃癌腹腔熱灌注化療的現狀與進展_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

李少卿 , 張珂誠 ,  陳凜

解放軍總醫院第一醫學中心普通外科（北京 100853）;

Corresponding?author：

陳凜, Email: chenlin@301hospital.com.cn

Keywords：

DOI：

10.7507/1007-9424.202007025

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李少卿, 張珂誠, 陳凜. 胃癌腹腔熱灌注化療的現狀與進展. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2020, 27(8): 922-926. doi: 10.7507/1007-9424.202007025 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	Rau B, Brandl A, Piso P, et al. Peritoneal metastasis in gastric cancer: results from the german database. Gastric Cancer, 2020, 23(1): 11-22.
4.	Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol, 2006, 32(6): 602-606.
5.	Coccolini F, Montori G, Ceresoli M, et al. Advanced gastric cancer: what we know and what we still have to learn. World J Gastroenterol, 2016, 22(3): 1139-1159.
6.	Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol, 2019, 4(10): 761-770.
7.	Rettenmaier MA, Micha JP, Bohart R, et al. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol, 2020, 244: 101-105.
8.	Cortés-Guiral D, Mohamed F, Glehen O, et al. Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Eur J Surg Oncol, 2020, [Online ahead of print].
9.	Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980, 40(2): 256-260.
10.	Kok HP, Cressman ENK, Ceelen W, et al. Heating technology for malignant tumors: a review. Int J Hyperthermia, 2020, 37(1): 711-741.
11.	Cesna V, Sukovas A, Jasukaitiene A, et al. Narrow line between benefit and harm: additivity of hyperthermia to cisplatin cytotoxicity in different gastrointestinal cancer cells. World J Gastroenterol, 2018, 24(10): 1072-1083.
12.	Zhu ZG, Tang R, Yan M, et al. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study. Dig Surg, 2006, 23(1-2): 93-102.
13.	崔書中, 巴明臣, 唐鴻生. 腹腔熱灌注化療技術方法變遷及展望. 中華臨床醫師雜志(電子版), 2011, 5(7): 2039-2042.
14.	中國抗癌協會腹膜腫瘤專業委員會, 廣東省抗癌協會腫瘤熱療專業委員會. 中國腹腔熱灌注化療技術臨床應用專家共識 (2019 版). 中華醫學雜志, 2020, 100(2): 89-96.
15.	Maehara Y, Okuyama T, Kakeji Y, et al. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg, 1994, 168(1): 36-40.
16.	陳新華, 羅俊, 劉浩, 等. 腹腔熱灌注化療預防局部進展期胃癌根治術后腹膜復發的研究進展. 中華胃腸外科雜志, 2018, 21(5): 593-599.
17.	Beeharry MK, Zhu ZL, Liu WT, et al. Correction to: prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer, 2019, 19(1): 1256.
18.	Golse N, Bakrin N, Passot G, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol, 2012, 106(2): 197-203.
19.	Costa WL, Coimbra FJ, Ribeiro HS, et al. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol, 2012, 10: 195.
20.	Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 1999, 85(3): 529-534.
21.	中國抗癌協會胃癌專業委員會. 胃癌腹膜轉移防治中國專家共識. 中華胃腸外科雜志, 2017, 20(5): 481-490.
22.	Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer, 1988, 61(2): 232-237.
23.	Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer, 1994, 73(8): 2048-2052.
24.	Yonemura Y, Ninomiya I, Kaji M, et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg, 1995, 19(3): 450-454, 455.
25.	Hirose K, Katayama K, Iida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology, 1999, 57(2): 106-114.
26.	Kunisaki C, Shimada H, Nomura M, et al. Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Surgery, 2002, 131(5): 521-528.
27.	Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg, 1998, 228(3): 347-354.
28.	Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology, 2001, 48(42): 1776-1782.
29.	Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase Ⅲ study. BMC Cancer, 2014, 14: 183.
30.	Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer. Cancer Commun (Lond), 2019, 39(1): 10.
31.	Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev, 2016, 48: 42-49.
32.	Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg, 2004, 139(1): 20-26.
33.	Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol, 2010, 17(9): 2370-2377.
34.	Blum Murphy M, Ikoma N, Wang X, et al. Phase Ⅰ trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and associated carcinomatosis or positive cytology. Ann Surg Oncol, 2020, 27(8): 2806-2811.
35.	Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer, 2017, 79: 1-14.
36.	Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients With Metastatic Gastric Cancer: A JSMO-ESMO Initiative Endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 2019, 30(1): 19-33.
37.	Hotopp T. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits? Surg Oncol, 2019, 28: 159-166.
38.	Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol, 2016, 23(6): 1971-1979.
39.	Sugarbaker PH. Peritoneal metastases from gastrointestinal cancer. Curr Oncol Rep, 2018, 20(8): 62.
40.	Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol, 2010, 2(2): 85-97.
41.	Manzanedo I, Pereira F, Rihuete Caro C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol, 2019, 26(8): 2615-2621.
42.	Pamela K, Matthias Z, Reinhold KR, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience in Austria. J Gastrointest Surg, 2018, 22(5): 884-893.
43.	Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP Study): a propensity score analysis. J Clin Oncol, 2019, 37(23): 2028-2040.
44.	Mielko J, Rawicz-Pruszyński K, Skórzewska M, et al. Conversion surgery with HIPEC for peritoneal oligometastatic gastric cancer. Cancers (Basel), 2019, 11(11): 1715.
45.	Beeharry MK, Ni ZT, Yang ZY, et al. Study protocol of a multicenter phase Ⅲ randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon Ⅱ trial. BMC Cancer, 2020, 20(1): 224.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. Rau B, Brandl A, Piso P, et al. Peritoneal metastasis in gastric cancer: results from the german database. Gastric Cancer, 2020, 23(1): 11-22.
4. Yonemura Y, Bandou E, Kawamura T, et al. Quantitative prognostic indicators of peritoneal dissemination of gastric cancer. Eur J Surg Oncol, 2006, 32(6): 602-606.
5. Coccolini F, Montori G, Ceresoli M, et al. Advanced gastric cancer: what we know and what we still have to learn. World J Gastroenterol, 2016, 22(3): 1139-1159.
6. Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol, 2019, 4(10): 761-770.
7. Rettenmaier MA, Micha JP, Bohart R, et al. A retrospective study comparing the efficacy of dose-dense chemotherapy, intraperitoneal chemotherapy and dose-dense chemotherapy with hyperthermic intraperitoneal chemotherapy in the treatment of advanced stage ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol, 2020, 244: 101-105.
8. Cortés-Guiral D, Mohamed F, Glehen O, et al. Prehabilitation of patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancy. Eur J Surg Oncol, 2020, [Online ahead of print].
9. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980, 40(2): 256-260.
10. Kok HP, Cressman ENK, Ceelen W, et al. Heating technology for malignant tumors: a review. Int J Hyperthermia, 2020, 37(1): 711-741.
11. Cesna V, Sukovas A, Jasukaitiene A, et al. Narrow line between benefit and harm: additivity of hyperthermia to cisplatin cytotoxicity in different gastrointestinal cancer cells. World J Gastroenterol, 2018, 24(10): 1072-1083.
12. Zhu ZG, Tang R, Yan M, et al. Efficacy and safety of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer patients with serosal invasion. A long-term follow-up study. Dig Surg, 2006, 23(1-2): 93-102.
13. 崔書中, 巴明臣, 唐鴻生. 腹腔熱灌注化療技術方法變遷及展望. 中華臨床醫師雜志(電子版), 2011, 5(7): 2039-2042.
14. 中國抗癌協會腹膜腫瘤專業委員會, 廣東省抗癌協會腫瘤熱療專業委員會. 中國腹腔熱灌注化療技術臨床應用專家共識 (2019 版). 中華醫學雜志, 2020, 100(2): 89-96.
15. Maehara Y, Okuyama T, Kakeji Y, et al. Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. Am J Surg, 1994, 168(1): 36-40.
16. 陳新華, 羅俊, 劉浩, 等. 腹腔熱灌注化療預防局部進展期胃癌根治術后腹膜復發的研究進展. 中華胃腸外科雜志, 2018, 21(5): 593-599.
17. Beeharry MK, Zhu ZL, Liu WT, et al. Correction to: prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study. BMC Cancer, 2019, 19(1): 1256.
18. Golse N, Bakrin N, Passot G, et al. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol, 2012, 106(2): 197-203.
19. Costa WL, Coimbra FJ, Ribeiro HS, et al. Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World J Surg Oncol, 2012, 10: 195.
20. Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer, 1999, 85(3): 529-534.
21. 中國抗癌協會胃癌專業委員會. 胃癌腹膜轉移防治中國專家共識. 中華胃腸外科雜志, 2017, 20(5): 481-490.
22. Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer, 1988, 61(2): 232-237.
23. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer, 1994, 73(8): 2048-2052.
24. Yonemura Y, Ninomiya I, Kaji M, et al. Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg, 1995, 19(3): 450-454, 455.
25. Hirose K, Katayama K, Iida A, et al. Efficacy of continuous hyperthermic peritoneal perfusion for the prophylaxis and treatment of peritoneal metastasis of advanced gastric cancer: evaluation by multivariate regression analysis. Oncology, 1999, 57(2): 106-114.
26. Kunisaki C, Shimada H, Nomura M, et al. Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. Surgery, 2002, 131(5): 521-528.
27. Yu W, Whang I, Suh I, et al. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg, 1998, 228(3): 347-354.
28. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomized controlled study. Hepatogastroenterology, 2001, 48(42): 1776-1782.
29. Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase Ⅲ study. BMC Cancer, 2014, 14: 183.
30. Wang FH, Shen L, Li J, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer. Cancer Commun (Lond), 2019, 39(1): 10.
31. Sugarbaker PH. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev, 2016, 48: 42-49.
32. Glehen O, Schreiber V, Cotte E, et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg, 2004, 139(1): 20-26.
33. Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol, 2010, 17(9): 2370-2377.
34. Blum Murphy M, Ikoma N, Wang X, et al. Phase Ⅰ trial of hyperthermic intraperitoneal chemoperfusion (HIPEC) with cisplatin, mitomycin, and paclitaxel in patients with gastric adenocarcinoma and associated carcinomatosis or positive cytology. Ann Surg Oncol, 2020, 27(8): 2806-2811.
35. Desiderio J, Chao J, Melstrom L, et al. The 30-year experience-a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer, 2017, 79: 1-14.
36. Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Management of Patients With Metastatic Gastric Cancer: A JSMO-ESMO Initiative Endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol, 2019, 30(1): 19-33.
37. Hotopp T. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits? Surg Oncol, 2019, 28: 159-166.
38. Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol, 2016, 23(6): 1971-1979.
39. Sugarbaker PH. Peritoneal metastases from gastrointestinal cancer. Curr Oncol Rep, 2018, 20(8): 62.
40. Yonemura Y, Elnemr A, Endou Y, et al. Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer. World J Gastrointest Oncol, 2010, 2(2): 85-97.
41. Manzanedo I, Pereira F, Rihuete Caro C, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer with peritoneal carcinomatosis: multicenter study of Spanish group of peritoneal oncologic surgery (GECOP). Ann Surg Oncol, 2019, 26(8): 2615-2621.
42. Pamela K, Matthias Z, Reinhold KR, et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): a single-center experience in Austria. J Gastrointest Surg, 2018, 22(5): 884-893.
43. Bonnot PE, Piessen G, Kepenekian V, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP Study): a propensity score analysis. J Clin Oncol, 2019, 37(23): 2028-2040.
44. Mielko J, Rawicz-Pruszyński K, Skórzewska M, et al. Conversion surgery with HIPEC for peritoneal oligometastatic gastric cancer. Cancers (Basel), 2019, 11(11): 1715.
45. Beeharry MK, Ni ZT, Yang ZY, et al. Study protocol of a multicenter phase Ⅲ randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon Ⅱ trial. BMC Cancer, 2020, 20(1): 224.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

胃癌腹腔熱灌注化療的現狀與進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content